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Anti-glomerular basement membrane (GBM) autoantibodies
are pathogenic in the development of anti-GBM disease. The
main target antigen is the non-collagenous 1 domain (NC1)
of collagen a3(IV); however, most antibodies can recognize
the NC1 of collagens a1, a2, a4 and a5(IV). In this study, we
analyzed the target antigens of anti-GBM autoantibodies to
determine their relationship to the severity of renal damage.
Natural anti-GBM autoantibodies were purified from 10
healthy individuals and from 57 patients with anti-GBM
disease who were divided into groups based on the degree
of renal damage defined by their serum creatinine at the time
of diagnosis. We found that the sera of all 57 patients
recognized a3(IV)NC1, while 23, 20, 28, and 48 patients also
recognized the NC1 of collagens a1, a2, a4, and a5(IV),
respectively. Natural anti-GBM autoantibodies recognized the
NC1 of collagens a3 and a4(IV). The sera of 7 patients with
the lowest level of renal damage mainly recognized the NC1
of collagens a3 and a5(IV). In the 20 patients with moderate
and the 30 with severe renal damage, all five target antigens
could be detected and most sera recognized three to five
different a chains simultaneously. Regression analysis
showed that only the level of autoantibodies against the
NC1 of collagen a3(IV) was a significant independent risk
factor for higher serum creatinine on diagnosis. Our study
shows that autoantibodies to the NC1 of collagen a3(IV) were
crucial in causing renal damage. Inter- and intra-molecular
epitope spreading can occur during the development of
human anti-GBM disease.
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Anti-glomerular basement membrane (GBM) disease is a
good example of autoantibody-mediated glomerulonephritis,
characterized by the presence of anti-GBM autoantibodies
in circulation and/or deposition along GBM. Rapid progres-
sive glomerulonephritis is the most common clinical feature.
Most patients are dialysis dependent on diagnosis or pro-
gress quickly to end-stage renal disease despite the plasma-
pheresis and intensive immunosuppressive therapy. However,
some patients could reserve part of their renal function
on diagnosis and during follow-up. Over the past few
decades, a subgroup of patients with normal renal func-
tion has been described.1–4 Whether they are at the early stage
or a different clinical phenotype of the disease is not
identified.
Anti-GBM autoantibodies are proven to be pathogenic
through passive transfer experiments.5–7 The major antigen
has been localized to the non-collagenous 1 (NC1) domain of
a3 chain of type IV collagen (a3(IV)NC1) in GBM. We
recently revealed the existence of natural autoantibodies
against GBM in normal human sera and further showed that
the antibodies recognize a3(IV)NC1 as well.8 However, in
human GBM, type IV collagen is composed of five a chains,
a1, a2, a3, a4, and a5.9,10 Patients with autoantibodies
against the other a chains, besides a3(IV)NC1, have been
reported widely.9,11–13 Hellmark et al.11 claims that sera from
more than 80% of patients have reactivity with other a
chains. Our previous study also shows that 49.3, 60.6, and
55.6% of patients could recognize a1, a4, and a5 chains,
respectively.13 Autoantibodies against a1(IV)NC1 are repor-
ted to have association with paraneoplastic syndromes,14 and
autoantibodies to a5(IV)NC1 have been implicated in the
pathogenesis of glomerulonephritis with skin blistering.15
However, the association of anti-GBM autoantibodies against
different target antigens and the severity of renal damage in
the disease has not been identified.
In the current study, a large cohort of Chinese patients with
anti-GBM disease were divided into three groups according to
their renal function (serum creatinine (Scr)) on diagnosis, and
the antigenic profiles of sera from these patients in addition to
natural anti-GBM autoantibodies from normal individuals were
determined using recombinant human a1, a2, a3, a4, and
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a5(IV)NC1 as antigens. Clinical data of the patients in different
groups were further investigated with the aim to find the
association between the target antigen distribution of anti-GBM
autoantibodies and the severity of renal damage.
RESULTS
The demographic and clinical data of patients
The demographic, clinical, and pathological data of patients in
the three groups are shown in Table 1. In total, 57 patients with
anti-GBM disease were divided into three groups according to
the Scr on diagnosis. In total, 7 patients with Scrp133mmol/l
were defined as group A (mild renal damage); 20 patients with
Scr 134–599mmol/l were defined as group B (moderate renal
damage); and 30 patients with Scr X600mmol/l were defined
as group C (severe renal damage). There was no significant
difference among the three groups in gender, age, hydrocarbon
exposure, prodromal infection, cigarette smoking, hemoptysis,
anti-neutrophil cytoplasmic antibody prevalence, interval from
onset to diagnosis, or treatment with plasma exchange. Patients
in group C had a significantly higher proportion of oliguria/
anuria (P¼ 0.001) and gross hematuria (P¼ 0.019), higher
Scr on diagnosis (P¼ 0.000), more crescents in glomeruli
(P¼ 0.017), and worse renal survival (P¼ 0.006) than those
in group A and B, as expected.
The frequencies of anti-GBM autoantibodies against
a1–5(IV)NC1 in patients with different levels of renal
function
The cutoff values of sera/IgG fractions to each antigen-
specific ELISA were 0.038/0.040 for a1(IV)NC1, 0.036/0.037
for a2(IV)NC1, 0.052/0.039 for a3(IV)NC1, 0.038/0.031 for
a4(IV)NC1, and 0.031/0.163 for a5(IV)NC1.
All sera from the 57 patients could recognize a3(IV)NC1,
whereas sera from 23 (40.1%), 20 (35.1%), 28 (49.1%), and
48 (84.2%) patients could recognize a1, a2, a4, and
a5(IV)NC1, respectively.
Of the seven patients in group A, none of the sera samples
could recognize a1(IV)NC1 or a2(IV)NC1, one (14.3%) serum
recognized a4(IV)NC1 and six (85.7%) sera recognized
a5(IV)NC1. In group B, 8/20 (40%) sera could recognize
a1(IV)NC1 and 7/20 (35%) sera recognized a2(IV)NC1. The
frequency of sera against a4(IV)NC1 increased to 45%. In group
C, the frequencies of sera against a1(IV)NC1 (15/30, 50%),
a2(IV)NC1 (13/30, 43.3%), and a4(IV)NC1 (18/30, 60%) were
further increased, compared with those in group B. The
frequency of sera against a5(IV)NC1 remained stable among
the three groups (Figure 1, Table 2). The relationship between
the frequencies of autoantibodies against each a chain and the
Scr of patients on diagnosis was analyzed. Positive correlations
were shown in the frequencies of antibodies against a1(IV)NC1
(r¼ 0.311, P¼ 0.019) and a4(IV)NC1 (r¼ 0.362, P¼ 0.006).
The types of target antigens recognized by anti-GBM
autoantibodies were also different in patients of different
groups. In group A, five (71.4%) sera recognized two types of
target antigens, which were a3(IV)NC1 and a5(IV)NC1, and
one serum recognized only a3(IV)NC1. Only one (14.3%)
serum recognized three types of target antigens, a3(IV)NC1,
a4(IV)NC1 and a5(IV)NC1. However, in group B, the
frequency of sera that recognized two types of target antigens
decreased to 30%, but 35% of the sera could recognize all the
five types of target antigens. In group C, only 23.3% of sera
recognized two types of target antigens and the frequency of
sera that recognized more than two types of target antigens
increased to 70%. Therefore, following the aggravation of
renal damage of patients from group A to group C, the types
of target antigens recognized by anti-GBM autoantibodies
were increased accordingly (Figure 2).
The levels of anti-GBM autoantibodies against a1–5(IV)NC1 in
patients with different levels of renal functions
The levels of anti-GBM autoantibodies (represented as the
absorbance values) against a3(IV)NC1 were significantly
Table 1 | Demographic data and clinical and pathological parameters of patients with different levels of renal function on
diagnosis
Group A Group B Group C P-value
Number 7 20 30
Age (years) 37.7±20.1 37.3±18.0 43.1±20.4 0.581
Gender (M/F) 4/3 13/7 17/13 0.832
Interval between onset and diagnosis (days) 100.5±59.7 60.6±73.4 46.5±45.7 0.179
Hydrocarbon exposure (%) 14.3 (1/7) 10 (2/20) 16.7 (5/30) 0.441
Prodromal infection (%) 42.9 (3/7) 50 (10/20) 36.7 (11/30) 0.645
Smoking (%) 57.1 (4/7) 30 (6/20) 23.3 (7/30) 0.212
Gross hematuria (%) 0 (0/7) 15 (3/20) 43.3 (13/30) 0.019
Nephrotic syndrome (%) 14.3 (1/7) 15 (3/20) 6.7 (2/30) 0.605
Hemoptysis (%) 25.6 (2/7) 35 (7/20) 33.3 (10/30) 0.953
Oliguria/anuria (%) 0 (0/7) 40 (8/20) 73.5 (22/30) 0.001
Serum creatinine (mmol/l) 86.7±31.5 424.7±122.7 1023.5±313.2 o0.001
ANCA (%) 0 (0/7) 40 (8/20) 23.3 (7/30) 0.125
Crescentic glomerulonephritis (%)a 50 (2/4) 100 (11/11) 92.9 (13/14) 0.017
Crescents in 485% of glomeruli (%) 25 (1/4) 54.5 (6/11) 71.4 (10/14) 0.236
Plasma exchange (%) 33.3 (2/6) 38.9 (7/18) 46.4 (13/28) 0.787
Renal survival at 1 year (%) 50 (3/6) 33.3 (6/18) 3.7 (1/27) 0.006
ANCA, anti-neutrophil cytoplasmic antibody. Group A, mild renal damage; Group B, moderate renal damage; Group C, severe renal damage.
aCrescentic glomerulonephritis indicates large crescents involving over 50% of the glomeruli.
P-values o0.05 are denoted in bold italics.
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higher than those of autoantibodies against a1, a2, a4, and
a5(IV)NC1 in each group (Table 2, Figure 3). The levels of
anti-GBM autoantibodies to a1, a2, a3, a4, and a5(IV)NC1
also showed an increasing tendency from group A to group C
and significant difference was obtained in autoantibodies
against a3(IV)NC1 (P¼ 0.000), a4(IV)NC1 (P¼ 0.010), and
a5(IV)NC1 (P¼ 0.008) (Figure 4).
The correlation between the level of autoantibodies
against a1–a5(IV)NC1 and the Scr of patients on diagnosis
was performed. Positive correlations were found in all five
types of antibodies (for autoantibodies against a1(IV)NC1,
r¼ 0.334, P¼ 0.011; for autoantibodies against a2(IV)NC1,
r¼ 0.344, P¼ 0.009; for autoantibodies against a3(IV)
NC1, r¼ 0.465, Po0.001; for autoantibodies against
a4(IV)NC1, r¼ 0.348, P¼ 0.008; and for autoantibodies
against a5(IV)NC1, r¼ 0.381, P¼ 0.003). However, regres-
sion analysis showed that only the level of autoantibodies
against a3(IV)NC1 was an independent risk factor for a
higher Scr of patients on diagnosis (r¼ 0.377, P¼ 0.042).
Association of the target antigens of anti-GBM
autoantibodies with other clinical manifestations of patients
In the 57 patients with anti-GBM disease, it was found that
patients with autoantibodies against a1(IV)NC1 had a higher
rate of hemoptysis than those who were negative for such
autoantibodies (12/23 vs 9/34, P¼ 0.048). Patients with
autoantibodies against a4(IV)NC1 had a significantly higher
rate of hydrocarbon exposure than those who were
negative for such autoantibodies (8/28 vs 0/25, P¼ 0.005).
No association was found between the target antigen
distribution and gender, prodromal infection, smoking,
hematuria, nephrotic proteinuria, or crescentic formation
in the glomeruli (P40.05).
Antigen specificity of natural autoantibodies against GBM
A total of 10 samples of natural autoantibodies against
GBM were almost exclusively reacted with a3(IV)NC1
(100%) and a4(IV)NC1 (100%), except for one sample
recognizing a5(IV)NC1 as well. The levels of natural auto-
antibodies against a3(IV)NC1 were significantly higher than
those against a4(IV)NC1 (0.180±0.083 vs 0.095±0.044,
P¼ 0.01).
Cross-reaction of autoantibodies against the five types of
target antigens
Three sera with reaction to all five types of target antigens
were chosen and inhibition ELISA was performed to detect
cross-reaction of autoantibodies against a1, a2, a3, a4, and
a5(IV)NC1 (Figure 5). The reaction between sera and
a3(IV)NC1 could not be inhibited by any of the other four
a chains. Similar finding was observed in the reaction
between sera and a4(IV)NC1. However, the reaction between
sera and a1(IV)NC1, a2(IV)NC1, and a5(IV)NC1 could be
partially inhibited by each of the other four a chains. This
implies that there was no cross-reaction between a3/
a4(IV)NC1 and other a chains, but the reaction of sera to
a1(IV)NC1, a2(IV)NC1, and a5(IV)NC1 might be a result of
partial cross-reaction.
DISCUSSION
In the current study, it was shown that all the 57 sera from
patients with anti-GBM disease recognized a3(IV)NC1, and
40, 35, 49, and 84% of sera also recognized a1, a2, a4, and
a5(IV)NC1, respectively. Autoantibodies against a3(IV)NC1
were most crucial in the pathogenesis of renal damage in
anti-GBM disease, as the level of these was an independent
risk factor for a higher Scr on diagnosis. These observations
were consistent with previous reports.11–13 However, differ-
ences in the antigen spectrum of anti-GBM autoantibodies
showed up when the patients were divided into three groups
according to their renal functions.
The three groups of patients were matched by age, gender,
hydrocarbon exposure, prodromal infection, cigarette
smoking, hemoptysis, and anti-neutrophil cytoplasmic anti-
body positive rate, which probably contributed to the antigen
spectrum and outcome of the kidney. We found that sera
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Figure 1 | The frequencies of sera against a1–a5(IV)NC1 in
each group of patients with different renal functions. Group A,
mild renal damage; Group B, moderate renal damage; Group C,
severe renal damage.
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from patients with damaged renal function (groups B and C)
recognized the other four a chains in addition to a3(IV)NC1,
whereas sera from patients with normal renal function
recognized merely a3(IV)NC1 and a5(IV)NC1. This finding
suggested that patients with damaged renal function had
broader antigen spectra compared with those with normal
renal function. Furthermore, significant association was
found between the frequency of sera against a4(IV)NC1
and the Scr of patients on diagnosis, which suggested that
autoantibodies against a4(IV)NC1 contributed to the renal
damage of patients. This finding was in concordance with a
previous study on animal models in which a4(IV)NC1 was
injected into rats and induced crescentic nephritis.16
Bolton et al. have proven the existence of intra- and inter-
molecular epitope spreading of B cells in an animal model
by showing that sera and kidney eluate from rats immunized
by the amino terminus of rat a3(IV)NC1 reveal reactivity
not only to the immunizing peptide but also to human and
rat a3(IV)NC1, and to human a4(IV)NC1.17,18 A recent
study indicates that a single T-cell epitope of Goodpasture
antigen is sufficient to initiate glomerulonephritis with
full clinical spectrum of anti-GBM disease and it could also
elicit an antibody response to diverse native GBM proteins.19
These animal models provide a clue of the possible
mechanism of inter-molecular epitope spreading in the
processing of anti-GBM disease. Because of ethical con-
siderations, it is impossible to perform similar experiments
in human beings to investigate the processing of epitope
spreading in human anti-GBM disease. However, our
observation showed that the antigen spectrum became
broader and the autoantibody load became higher grad-
ually as renal function was getting worse. If patients with
different renal function were at different stages of disease
progression, our findings may provide a clue of inter-
molecular epitope spreading in the development of human
anti-GBM disease.
In the current study, at least three types of epitopes in
a3(IV)NC1 were found with reactivity to anti-GBM auto-
antibodies in sera of normal individuals and patients. One
restrictive epitope with reaction to the natural anti-GBM
Table 2 | The frequencies and levels of anti-GBM autoantibodies against each target antigen in patients with different levels of
renal function
P-value
Antigen Group A Group B Group C A vs B B vs C A vs C A vs B vs C
a1(IV)NC1
Frequency 0% (0/7) 40% (8/20) 50%(15/30) 0.068 0.487 0.028 0.015
Absorbance values (mean±s.d.) 0.152±0.09 0.263±0.240 0.116
a2(IV)NC1
Frequency 0% (0/7) 35% (7/20) 43.3%(13/30) 0.137 0.556 0.038 0.031
Absorbance values (mean±s.d.) 0.135±0.104 0.258±0.185 0.150
a3(IV)NC1
Frequency 100% (7/7) 100% (20/20) 100% (30/30)
Absorbance values (mean±s.d.) 0.264±0.239 0.708±0.400 0.997±0.269 0.003 0.008 0.000 0.000
a4(IV)NC1
Frequency 14.3% (1/7) 45% (9/20) 60% (18/30) 0.082 0.486 0.023 0.069
Absorbance values (mean±s.d.) 0.192±0.114 0.389±0.257 0.010
a5(IV)NC1
Frequency 85.7% (6/7) 70% (14/20) 93.3% (28/30) 0.543 0.069 0.534
Absorbance values (mean±s.d.) 0.068±0.035 0.351±0.319 0.484±0.314 0.004 0.200 0.000 0.008
GBM, glomerular basement membrane. Group A, mild renal damage; Group B, moderate renal damage; Group C, severe renal damage.
P-values o0.05 are denoted in bold.
0
10
20
30
40
50
60
70
80
90
100
Groups
Pe
rc
en
ta
ge
 (%
)
1 antigen 0 14.3 25 6.7
2 antigens 90 71.4 30 23.3
3 antigens 10 14.3 10 23.3
4 antigens 0 0 0 13.3
5 antigens 0 0 35 33.3
NAA Group A Group B Group C
Figure 2 | The types of target antigens recognized by
anti-glomerular basement membrane (GBM) autoantibodies
compared among normal individuals and patients with
different levels of renal function. The x axis represents the four
groups, including natural autoantibodies against GBM and sera of
patients in groups A, B, and C. The y axis represents the frequency
of autoantibodies against different types of target antigens,
from one type to all five types of a1–5(IV)NC1. NAA, natural
autoantibody. Group A, mild renal damage; Group B, moderate
renal damage; Group C, severe renal damage.
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autoantibodies had no cross-reaction to a4(IV)NC1 or
any other a chains. The other major pathogenic epitope
with reaction to the patients with normal renal function
may have cross-reaction with a5(IV)NC1 but no cross-
reaction with a1(IV)NC1 or a2(IV)NC1, as no serum
reacting with a1(IV)NC1 or a2(IV)NC1 was found in patients
of group A. The third pervasive epitope with reaction to
sera from patients with renal damage may have the most
general cross-reaction with all the other a chains. Thus, this
finding suggested that intra-molecular epitope spreading
may occur in the progress of anti-GBM disease, as all the
three types of epitopes in a3(IV)NC1 could be detected in
patients of group C.
Our previous study revealed that natural autoantibodies
against GBM are more restricted to a3(IV)NC1 than auto-
antibodies from patients with anti-GBM disease.8 The current
study showed that the natural autoantibodies also recognized
a4(IV)NC1 and none of them recognized a1 or a2(IV)NC1.
Structurally, a3a4a5(IV) network, which is composed of triple-
helical protomers (Goodpasture protomers) identified in the
GBM, represents the native form of the anti-GBM autoanti-
gen.20 In the evolution process of type IV collagen, a1 and a2
chains emerge first, then a5 chain shows up, followed by a3 and
a4 chains.21,22 Therefore, a3(IV)NC1 and a4(IV)NC1, which
were exclusively recognized by natural autoantibodies, always
connect each other either on the structure or in the evolution
process. It made sense in the generation mechanism of natural
autoantibodies, which were presumed to be the results of
immune evasion and immune tolerance.
One case that had antibodies against a1(IV)NC1
rather than a3(IV)NC1 was previously reported, presenting
with recurrent hemoptysis and abnormal chest radiograph,
and finally was revealed to be paraneoplastic syndrome.14
In the current study, it was interesting to find that
autoantibodies to a1(IV)NC1 were associated with hemop-
tysis, and autoantibodies to a4(IV)NC1 were associated
with hydrocarbon exposure. Although it is suggested that
the autoantibodies against al, a2, a4, and a5(IV)NC1 may
not induce severe renal damage,14 the clinical significance
of such autoantibodies needs further investigations.
In summary, we mapped the profile of antigen spectrum
of a cohort of Chinese patients with anti-GBM disease and
found that sera of patients with different levels of renal
function had different spectra of target antigens. We provided
evidence that inter- and intra-molecular epitope spreading
might occur during the disease processing.
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Figure 3 | The level of anti-glomerular basement membrane
(GBM) autoantibodies against a1–a5(IV)NC1 in each serum
from patients with different levels of renal function. The
diamonds represent the absorbance value of autoantibodies
in each patient. The bars indicate the mean absorbance values.
The mean absorbance value of anti-GBM autoantibodies against
a3(IV)NC1 was significantly higher than that against a1, a2, a4,
and a5(IV)NC1 in each group.
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Figure 4 |The mean level of anti-glomerular basement mem-
brane (GBM) autoantibodies against a1–a5(IV)NC1 compared
among patients with different levels of renal function.
The mean absorbance values of anti-GBM autoantibodies to
a1–a5(IV)NC1 showed an increasing tendency from group A to
group C. The regression analysis showed that only the level of
autoantibodies against a3(IV)NC1 was an independent risk factor
for a higher serum creatinine in patients on diagnosis (r¼ 0.377,
P¼ 0.042).
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MATERIALS AND METHODS
Sera and patients
Normal human sera were obtained from 10 healthy blood donors
and were negative of anti-GBM autoantibodies in routine ELISA.
Sera from 57 patients with anti-GBM disease, diagnosed in Peking
University First Hospital during 2001–2007, were collected and divided
into three groups according to the Scr on diagnosis. A total of
7 patients with Scrp133mmol/l were defined as group A; 20 patients
with Scr 134–599mmol/l were defined as group B; and the other
30 patients, with Scr X600mmol/l, were defined as group C. Group A
represented patients with mild renal damage, group B represented
patients with moderate renal damage, and group C represented
patients with severe renal damage. On diagnosis, sera of all
patients were positive for anti-GBM autoantibodies by ELISA using
bovine a(IV)NC1 as solid phase antigen and confirmed by ELISA
using recombinant human a3(IV)NC1. In total, 29 patients (4/7 in
group A, 11/20 in group B, and 14/30 in group C) received renal
biopsy and all of them were demonstrated with linear deposition of
IgG, with or without C3, along GBM by direct immunofluorescence.
Sera from the 57 patients were collected on diagnosis before
immunosuppressive treatment and plasmapheresis. In total, 20 sera
samples obtained from normal blood donors were used as normal
controls. All the sera samples were stored at 20 1C until use.
Informed consent was obtained for sampling tissue and blood.
Preparation of natural autoantibodies against GBM
Natural autoantibodies against GBM were prepared as previously
described.23 In brief, purified bovine a(IV)NC1 (10 mg) was
coupled to 10 ml cyanogen bromide-activated Sepharose 4B gel
(3.5 g, Amersham Pharmacia, Uppsala, Sweden) with 0.1 M
NaHCO3 and 0.5 M NaCl, pH 8.3 as coupling buffer at room
temperature for 2 h and blocked with 0.2 M glycine, pH 8.0 at room
temperature for 2 h. IgG fractions were purified using protein G
affinity chromatography (Amersham Pharmacia) from sera of each
of the 10 normal healthy blood donors. Normal human IgG
fractions were applied to the affinity column coupled with purified
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Figure 5 |Cross-reaction of autoantibodies against a1, a2, a3, a4, and a5(IV)NC1 measured by antigen inhibition ELISA. y axis:
the mean of absorbance value (OD) of a serum bound with the antigen coated in the microtiter plates. x axis: different concentrations of
the inhibitors of a1–a5(IV)NC1 for preincubation with the serum. (a) Reaction of a serum with a1(IV)NC1 inhibited by a1–a5(IV)NC1;
(b) reaction of a serum with a2(IV)NC1 inhibited by a1–a5(IV)NC1; (c) reaction of a serum with a3(IV)NC1 inhibited by a1–a5(IV)NC1;
(d) reaction of a serum with a4(IV)NC1 inhibited by a1–a5(IV)NC1; and (e) reaction of a serum with a5(IV)NC1 inhibited by a1–a5(IV)NC1.
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bovine a(IV)NC1 with 0.01 mol/l phosphate buffer solution, pH 7.4
as starting buffer and 0.05 mol/l glycine, 0.5 mol/l NaCl, pH 2.7 as
eluting buffer, at a flow rate of 1 ml/min at room temperature.
Natural autoantibodies were eluted, neutralized to pH 7.0,
concentrated, and dialyzed against phosphate buffer solution.
Preparation of recombinant human a1, a2, a3, a4, and
a5(IV)NC1
Recombinant human a1, a2, a3, a4, and a5(IV)NC1 were produced
as described earlier.5,24 In brief, cDNA from the NC1 domain of
human type IV collagen a1, a2, a3, a4, and a5 was ligated to a type
X collagen triple-helix leader sequence and subcloned into the
pcDNA vector. The constructs were then stably transfected into a
human embryonic kidney cell line (HEK 293), and recombinant
proteins were harvested and purified from the medium.
Detection of the antigen specificity of anti-GBM
autoantibodies
The recombinant human a1, a2, a3, a4, and a5(IV)NC1 were diluted
to 0.5mg/ml with 0.05 mol/l bicarbonate buffer (pH 9.6) and coated onto
half of the wells of a polystyrene microtiter plate (Nunc immunoplate,
Nunc, Roskiled, Denmark). The other half were coated with BSA (bovine
serum albumin) diluted to 0.5mg/ml with 0.05 mol/l bicarbonate buffer
as antigen-free wells to exclude non-specific binding. The volume of
each well was 50ml. Incubation was carried out at 37 1C for 60 min. Test
sera were diluted to 1:100 and the natural autoantibodies against GBM
was diluted 1:3, in phosphate-buffered saline containing 0.05% Tween-20
and 0.2% BSA (PBST-BSA) and added in duplication to both antigen-
coated wells and antigen-free wells, at 37 1C for 30 min. Every plate
contained positive, negative, and blank (PBST) controls. Sera from
patients with pre-determined high titers of autoantibodies against a1, a2,
a3, a4, and a5(IV)NC1 were selected as positive controls. After washing
thrice, alkaline phosphatase-conjugated goat anti-human IgG (Fc
specific, Sigma, St Louis, MO, USA) diluted 1:6000 was added.
Incubation resumed at 37 1C for 30 min. After washing, P-nitrophenyl
phosphate (1 mg/ml; Sigma) in substrate buffer (1 M diethanolamine,
0.5 mM MgCl2, PH 9.8) was used as substrate, and color development
was measured spectrophotometrically at 405 nm (Bio-Rad, Tokyo, Japan)
30 min later. When standard errors greater than 10% were found,
samples were re-examined. Absorbance values from anti-BSA ELISA
were subtracted from the results of anti-a1, a2, a3, a4, and a5(IV)NC1
ELISA. A total of 20 sera diluted 1:100 and 20 IgG fractions from
healthy blood donors diluted equivalent to the concentration of
natural autoantibodies were used to build up the cutoff values using
meanþ 2 s.d.
Inhibition ELISA
To detect the cross-reaction of autoantibodies against a1, a2, a3, a4,
and a5(IV)NC1, inhibition ELISA was performed using sera from
three patients that could recognize all the five a chains. Polystyrene
microtiter plates were coated with a1, a2, a3, a4, and a5(IV)NC1,
as described above. Sera were diluted in phosphate buffer solution to
obtain approximately the same absorbance value after 1 h at room
temperature. The diluted sera were preincubated with a1, a2, a3, a4,
and a5(IV)NC1, respectively, at increasing concentrations from 0.02
to 20 mg/ml overnight at 4 1C. The mixtures were transferred to the
antigen-coated microtiter plates and the bound autoantibodies were
detected with alkaline phosphatase-conjugated secondary anti-
bodies, as described above.
Statistical analysis
Differences of quantitative parameters between two groups
were assessed using the Student’s t-test (for data that were normally
distributed) or nonparametric test (for data that were not normally
distributed). Differences of qualitative results between two groups
were compared using w2-test. Fisher’s exact test was used in the
comparison of autoantibody frequency between group A and each of
the other two groups. Spearman’s rank correlation and linear
regression analysis were performed to analyze the relationship between
the frequencies and levels of autoantibodies against each target antigen
and Scr of patients on diagnosis. P-value o0.05 was considered
significant.
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